cbenz@buckinstitute.org
benz@itsa.ucsf.edu
(415) 209-2092 (voice)
(415) 209-2232 (fax)

Box 1270, UCSF; San Francisco, CA 94143-1720
or
Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945

University of California, Los Angeles, B.S., 1968, Biochemistry
University of Michigan, Ann Arbor, M.D., 1972, Medicine
VGH/CCABC & UBC, Vancouver, B.C., Canada, 1972-1978, Int Med/Hem-Onc
Yale Univ. School of Med, New Haven, CT, 1978-79, Oncology

Selected from over 250 articles & texts

Chang C-H, Scott GK, Kuo W-L, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, Benz CC. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 14: 1617-1622, 1997.

Benz C, O'Hagan RC, Richter B, Scott GK, Chang C-H, Xiong X, Chew K, Ljung B-M, Edgerton S, Thor A, Hassell JA. HER2/neu. and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15: 1513-1525, 1997.

Johnston SRD, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC. Comparison of estrogen receptor DNA-binding in untreated and antiestrogen-resistant human breast tumors. Cancer Res. 57: 3723-3727, 1997.

Lu B, Liang XS, Scott GK, Chang C-H, Baldwin MA, Thomas T, Benz CC. Polyamine inhibition of estrogen receptor (ER) DNA-binding and ligand-binding functions. Breast Cancer Res. Treat. 48: 243-257, 1998.

Eppenberger U, Kueng W, Schlaeppi J-M, Roesel JL, Benz CC, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J. Clin. Oncol. 16: 3129-3136, 1998.

Neve R, Chang C, Scott GK, Wong A, Friis RR, Hynes NE, Benz CC. The epithelium-specific Ets transcription factor ESX is associated with mammary gland development and involution. FASEB J. 12: 1541-1550, 1998.

Liang X, Lu B, Scott GK, Chang C-H, Baldwin MA, Benz CC. Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol. Cell. Endocrinol. 146: 151-161, 1998.

Johnston SRD, Lu B, Scott GK, Kushner P, Smith IE, Dowsett M, Benz CC. Increased AP-1 DNA binding and Jun N-terminal kinase in human breast tumors with acquired tamoxifen resistance. Clin. Cancer Res. 5: 241-256, 1999.

Benz CC. Transcription factors and breast cancer. Endocrine-Related Cancer 5: 271-282, 1998.

Chang C-H, Scott GK, Baldwin MA, Benz CC. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor ESX confers potent transactivating capacity and binds to TATA-binding protein (TBP). Oncogene 24: 3682-3695, 1999.

Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC. Emerging antibody-based HER2(ErbB2/neu) therapeutics. Breast Disease 11: 113-124, 2000.

Benz CC and Tripathy. ErbB2 overexpression in breast cancer: biology and clinical translation. J. WomenÕs Cancer 2: 33-40, 2000.

Noonberg SB and Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59: 753-767, 2000.

Chiang S-Y, BŸrli RW, Benz CC, Gawron L, Scott GK, Dervan PB, Beerman TA. Targeting the Ets binding site of the HER2/neu promoter with pyrrole-imadazole polyamides. J. Biol. Chem. 275: 24246-24254, 2000.

Whittal RM, Benz CC, Scott G, Semyonov J, Burlingame AL, Baldwin MA. Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and hence, DNA binding. Biochemistry 39: 8406-8417, 2000.

Thor AD, Liu S, Edgerton S, Moore D II, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB2 (HER2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18: 3230-3239, 2000.

Scott GK, Chang C-H, Erny KM, Xu F, Fredericks WJ, Rauscher III FJ, Thor AD, Benz CC. Ets regulation of the erbB2 promoter. Oncogene 19: 6490-6502, 2000.

Eppenberger-Castori S, Kueng W, Benz CC, Paris K, Caduff R, Bannwart F, Fink D, Dieterich H, Braschler C, von Castelberg B, MŸller H, Eppenberger U. Prognostic and predictive significance of ErbB2 breast tumor levels measured by enzyme immunoassay. J. Clin. Oncol. 19: 645-656,2001.

Neve RM, Nielsen UB, Kirpotin DB, Poul M-A, Marks JD, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem. Biophys. Res. Comm. 280: 274-279, 2001.

Benz CC and Marden C. Ets transcription factors. In: Wiley Encyclopedia of Molecular Medicine (TE Creighton, ed) John Wiley & Sons, Inc. New York 2002, pp 1209-1212.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen U, Marks J, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced anticancer efficacy due to targeted delivery. Clin. Cancer Res. 8: 1172-1181, 2002.

Baldwin MA and Benz CC. Redox control of zinc finger proteins. Meth. Enzymol. 353: 54-69, 2002.

Scott GK, Marden C, Xu F, Kirk L, and Benz CC. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol. Cancer Therapeutics 1: 385-392, 2002.

Neve RM, Ylstra B, Chang C-H, Albertson DG, and Benz CC. ErbB2 activation of ESX gene expression. Oncogene 21: 3934-3938, 2002.

Quong J, Eppenberger-Castori S, Moore II D, Scott GK, Birrer MJ, Kueng W, Eppenberger U, and Benz CC. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res. Treat. 76: 221-236, 2002.

Eppenberger-Castori S, Moore II D, Thor AD, Edgerton SM, Kueng W, Eppenberger U, and Benz CC. Age-associated biomarker profiles of human breast cancer. Int. J. Biochem. & Cell Biology 34: 1318-1330, 2002.

Meza JE, Scott GK, Benz CC, and Baldwin MA. Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers. Anal. Biochem. 320: 21-31, 2003.

Benz CC, Clarke CA, and Moore DH. Geographic excess of estrogen receptor-positive breast cancer. Cancer Epidemiology, Biomarkers and Prevention 12: 1523-1527, 2003.

Benz CC. HER2 and the endocrine responsiveness of breast cancer. Oncology Exchange 3: 8-11,21, 2004.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, and Drummond DC. Development of ligand targeted liposomes for cancer therapy. Expert Opin. Ther. Targets 8: 335-353. 2004.

Hwang ES, Chew T, Shiboski S, Farren G, Benz CC, and Wrensch M. Risk factors for estrogen receptor-positive breast cancer. Arch. Surg. 140: 58-62, 2005.

Zhou Y, Eppenberger-Castori, Marx C, Yau C, Scott GK, Eppenberger U, and Benz CC. Activation of nuclear factor-B (NFB) identifies a high-risk subset of hormone-dependent breast cancers. Int. J. Biochem. Cell Biol. 37: 1130-1144, 2005.

Drummond DC, Noble CO, Kirpotin DB, GuoZ, Scott GK, and Benz CC. Clinical development of histone deacetylalase inhibitors as anticancer agenst. Ann. Rev. Pharmacol. Toxicol. 45: 495-528, 2005.

Zhou Y, Eppenberger-Castori S, Eppenberger U, and Benz CC. The NFB pathway and endocrine resistant breast cancer. Endocrine-Related Cancer 12: S37-S46; 2005.

Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Park J, Kirpotin DB, and Benz CC. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin. Cancer Res. 11: 3392-3401; 2005.

Benz CC. Devious signals from NFB driving breast cancer progression. Breast Cancer Online (www.bco.org) 8(5); 2005.

Parmar H, Melov S, Ljung B-M, Cunha GR, and Benz CC. Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase. The Breast 14: 256-263, 2005.

Atsriku C, Scott GK, Benz CC, and Baldwin MA. Reactivity of zinc finger cysteines: chemical modifications within labile zinc fingers in estrogen receptor. J. Am. Soc. Mass Spectrom. 16: 2017-2026, 2005.

Scott GK, Atsriku C, Kaminker P, Held J, Gibson B, Baldwin MA, and Benz CC. Vitamin K3 (menadione) induced oncosis associated with keratin 8 phosphorylation and histone H3 arylation. Mol. Pharmacol. 68: 606-615, 2005.

Neve RM, Parmar H, Amend C, Chen C, Rizzino A, and Benz CC. Identification of an epithelial-specific enhancer regulating ESX expression. Gene 367: 118-125, 2006.

Scott GK, Mattie MD, Berger CE, Benz SC, and Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66: 1277-1281, 2006.

Marx C, Berger C, Xu F, Amend C, Scott GK, Hann B, Park JW, and Benz CC. Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. ASSAY and Drug Development Technologies (in press), 2006.

4/28/06